Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Jul;42(7):452-463.

Cancer Immunotherapy, Part 2: Efficacy, Safety, and Other Clinical Considerations

C Lee Ventola

Cancer Immunotherapy, Part 2: Efficacy, Safety, and Other Clinical Considerations

C Lee Ventola. P T. 2017 Jul.

Abstract

This article, the second in a series of three, provides an overview of the efficacy and safety of cancer immunotherapies ranging from monoclonal antibodies to vaccines, including additional clinical considerations regarding immune checkpoint blockers.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Representative Immune-Related Adverse Events Observed With Immune Checkpoint Blockers,
See this image and copyright information in PMC

References

    1. Weiner LM. Cancer immunology for the clinician. Clin Adv Hematol. 2015;13(5):299–306. - PubMed
    1. Zugazagoitia J, Guedes C, Ponce S, et al. Current challenges in cancer treatment. Clin Ther. 2016;38(7):1551–1566. - PubMed
    1. Alatrash G, Jakher H, Stafford PD, Mittendorf EA. Cancer immunotherapies, their safety and toxicity. Expert Opin Drug Saf. 2013;12(5):631–645. - PubMed
    1. Karlitepe A, Ozalp O, Avci O. New approaches for cancer immunotherapy. Tumor Biol. 2015;36(6):4075–4078. - PubMed
    1. Klener P, Jr, Otahal P, Lateckova L, Klener P. Immunotherapy approaches in cancer treatment. Curr Pharm Biotechnol. 2015;16(9):771–781. - PubMed

LinkOut - more resources